LON:MXCT MaxCyte (MXCT) Share Price, News & Analysis GBX 0.82 -0.03 (-3.13%) As of 05/11/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About MaxCyte Stock (LON:MXCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MaxCyte alerts:Sign Up Key Stats Today's Range 0.81▼ 0.8450-Day Range 0.68▼ 0.8952-Week Range 147.69▼ 407.84Volume334,651 shsAverage Volume42,065 shsMarket Capitalization£868.52 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions. Let’s Build Better Cells Together. To learn more, please visit www.maxcyte.com Read More Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MXCT Stock News HeadlinesMaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...May 13 at 6:25 PM | finance.yahoo.comMaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital AccessMarch 27, 2026 | tipranks.comWhat is “gold skimming”?Former $900 million hedge fund manager Larry Benedict has developed a strategy he calls Gold Skimming - a way to target cash payouts from gold markets without buying a single ounce, mining stock, or ETF. With a reported 73% win rate across 19 trades and potential payouts of $2,975, $3,781, and $6,786 in a single day, Benedict has put together a free step-by-step walkthrough showing how it works whether gold climbs or pulls back.May 14 at 1:00 AM | Brownstone Research (Ad)MaxCyte Appoints Parmeet Ahuja as Chief Financial OfficerMarch 23, 2026 | markets.businessinsider.comMaxCyte Faces Nasdaq Noncompliance Over Minimum Bid PriceMarch 20, 2026 | tipranks.comMaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug DiscoveryFebruary 25, 2026 | finance.yahoo.comMaxCyte, Inc. to Release Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026February 23, 2026 | quiverquant.comQMaxCyte Inc.January 28, 2026 | marketwatch.comSee More Headlines MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at GBX 1.58 at the start of the year. Since then, MXCT stock has decreased by 48.3% and is now trading at GBX 0.82. How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include HSBC (HSBA), EQTEC (EQT), Grafton Group (GFTU), Lloyds Banking Group (LLOY) and Marks and Spencer Group (MKS). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryBusiness Services Current SymbolLON:MXCT CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£45.08 million Net Margins-120.39% Pretax MarginN/A Return on Equity-16.71% Return on Assets-11.07% Debt Debt-to-Equity Ratio9.70 Current Ratio12.39 Quick Ratio14.38 Sales & Book Value Annual Sales£33.03 million Price / Sales0.03 Cash FlowGBX 0.41 per share Price / Cash Flow1.97 Book ValueGBX 203.85 per share Price / Book0.00Miscellaneous Outstanding Shares106,319,000Free FloatN/AMarket Cap£868.52 thousand OptionableNot Optionable Beta1.13 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (LON:MXCT) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersOne coin wired into Elon's visionThe Kevin Warsh Fed takeover is here. And he's brought a thesis with him that almost nobody is talking about. ...Crypto 101 Media | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
